In a blow to Eli Lilly, Novo Nordisk lands FDA OK for their next big entry in the diabetes market: Ozempic
An energized FDA has come through with an approval of Novo Nordisk’s once-weekly GLP-1 diabetes drug semaglutide, opening the door to a market many analysts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
